Andere Kunden interessierten sich auch für
![Selective Estrogen Receptor Modulator]( "Selective Estrogen Receptor Modulator")
Selective Estrogen Receptor Modulator19,99 €![Selective Serotonin Releasing Agent]( "Selective Serotonin Releasing Agent")
Selective Serotonin Releasing Agent19,99 €![Quantum Modeling of Spin-Selective Processes of the Triplet State]( "Quantum Modeling of Spin-Selective Processes of the Triplet State")
Quantum Modeling of Spin-Selective Processes of the Triplet State51,99 €![Preparation and testing of selective catalysts containing noble metals]( "Preparation and testing of selective catalysts containing noble metals")
Preparation and testing of selective catalysts containing noble metals34,99 €![Molecularly Imprinted Receptor Targeting Lung Cancer Biomarker]( "Molecularly Imprinted Receptor Targeting Lung Cancer Biomarker")
Molecularly Imprinted Receptor Targeting Lung Cancer Biomarker46,99 €![Calix[4]arene based ion-selective electrodes]( "Calix[4]arene based ion-selective electrodes")
Calix[4]arene based ion-selective electrodes23,99 €![Supramolecular Science]( "Supramolecular Science")
Supramolecular Science110,99 €
![Calix[4]arene based ion-selective electrodes](https://bilder.buecher.de/produkte/45/45354/45354132n.jpg "Calix[4]arene based ion-selective electrodes")
A selective glucocorticoid receptor agonist (SEGRA), sometimes called a dissociated glucocorticoid receptor agonist (DIGRA), is a type of experimental drug that is designed to share many of the desirable anti-inflammatory and immunosuppressive properties of classical glucocorticoid drugs but with fewer side effects such as skin atrophy. As of November 2010[update], Phase II clinical trials with the SEGRA mapracorat investigating the topical treatment of atopic dermatitis and inflammation following cataract surgery have been completed, but no results are available. Such trials attempt to determine whether the theoretical concept translates into an actual clinical benefit.